TY - JOUR
T1 - The role of natriuretic peptides in heart failure
AU - Correa de Sa, Daniel D.
AU - Chen, Horng H.
N1 - Funding Information:
Improved Management of Patients With Congestive Heart Failure; MONICA—Monitoring Trends and Determinants in Cardiovascular Disease; NAPA—Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery; NHANES—National Health and Nutritional Examination Survey; STARBRITE—Strategies for Tailoring Advanced Heart Failure Regimens in the Out-patient Setting: Brain Natriuretic Peptide Levels Versus the Clinical Congestion Score; STARS-BNP—Systolic Heart Failure Treatment Supported by BNP; Val-HeFT— Valsartan Heart Failure Trial; VMAC—Vasodilation in the Management of Acute Congestive Heart Failure.
Funding Information:
Horng H. Chen has a research grant from Scios and is a consultant for Cogenesys. No other potential conflicts of interest relevant to this article were reported.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2008
Y1 - 2008
N2 - Heart failure is a clinical syndrome associated with progressive cardiac, vascular, and renal dysfunction. Regardless of the initial injury, investigations have demonstrated that neurohormones play an important role in the complex multiorgan and cellular adaptations. Natriuretic peptides play a key role in this process, antagonizing the actions of the renin-angiotensin-aldosterone system, thus promoting vasodilatation and natriuresis. Other important physiologic properties of the natriuretic peptides are prolusitropic, sympathoinhibitory, antiproliferative, anti-ischemic, anti-inflammatory, and antioxidative. Administering exogenous natriuretic peptide is a US Food and Drug Administration-approved therapy for patients with advanced decompensated congestive heart failure. Also, measuring natriuretic peptide levels has diagnostic and prognostic value. More studies are needed to define the full potential of this unique family of endogenous peptides.
AB - Heart failure is a clinical syndrome associated with progressive cardiac, vascular, and renal dysfunction. Regardless of the initial injury, investigations have demonstrated that neurohormones play an important role in the complex multiorgan and cellular adaptations. Natriuretic peptides play a key role in this process, antagonizing the actions of the renin-angiotensin-aldosterone system, thus promoting vasodilatation and natriuresis. Other important physiologic properties of the natriuretic peptides are prolusitropic, sympathoinhibitory, antiproliferative, anti-ischemic, anti-inflammatory, and antioxidative. Administering exogenous natriuretic peptide is a US Food and Drug Administration-approved therapy for patients with advanced decompensated congestive heart failure. Also, measuring natriuretic peptide levels has diagnostic and prognostic value. More studies are needed to define the full potential of this unique family of endogenous peptides.
UR - http://www.scopus.com/inward/record.url?scp=45849110678&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45849110678&partnerID=8YFLogxK
U2 - 10.1007/s11886-008-0032-2
DO - 10.1007/s11886-008-0032-2
M3 - Review article
C2 - 18489861
AN - SCOPUS:45849110678
SN - 1523-3782
VL - 10
SP - 182
EP - 189
JO - Current cardiology reports
JF - Current cardiology reports
IS - 3
ER -